TELO
Telomir Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.04
−0.95%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +63.6%
- EBIT
- +62.4%
- EPS
- —
- Free cash flow
- -55.1%
- Operating cash flow
- -55.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +104.0%
- EPS
- +90.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -32.6%
- EBIT
- +13.9%
- Net income
- +37.0%
- EPS
- +41.1%
- Free cash flow
- +27.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026